Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
(RTTNews) - Revelation Biosciences, Inc. (REVB), a clinical-stage life sciences company, announced on Monday that the FDA has accepted its Investigational New Drug (IND) application for Gemini, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results